Gvos M 1 Tablet is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.3mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake by muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, minimizing postprandial hyperglycemia. The synergistic action of these three agents provides comprehensive management of blood sugar by targeting multiple pathophysiological mechanisms of type 2 diabetes. Gvos M 1 Tablet is indicated for patients inadequately controlled on diet, exercise, and monotherapy with either sulfonylureas or metformin alone. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerance. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia, particularly due to Glimepiride. This medication should be used under medical supervision, with caution in patients with renal or hepatic impairment, and contraindicated in cases of diabetic ketoacidosis or severe infections.